Boston Scientific Corp (BSX)

The liquidity ratios for Boston Scientific Corp. indicate the company's ability to meet its short-term obligations with its current assets.

1. Current Ratio:
- The current ratio has been fluctuating over the past five years, ranging from 0.97 in 2019 to 1.82 in 2020. In 2023, the current ratio stands at 1.32, showing a slight decrease from the previous year.
- A current ratio above 1 indicates that the company has more current assets than current liabilities to cover its short-term obligations.
- Although the current ratio has decreased in 2023, it is still above 1, suggesting that Boston Scientific has enough current assets to meet its current liabilities.

2. Quick Ratio:
- The quick ratio demonstrates the company's ability to cover its short-term liabilities with its most liquid assets, excluding inventory.
- Boston Scientific's quick ratio has similarly fluctuated over the years, with a significant increase from 0.64 in 2019 to 1.14 in 2020. However, in 2023, the quick ratio has dropped to 0.79.
- A quick ratio above 1 is considered healthy, indicating that the company can meet its short-term obligations without relying on selling inventory.
- The decrease in the quick ratio from 2022 to 2023 suggests that Boston Scientific may have a lower level of liquid assets relative to its current liabilities.

3. Cash Ratio:
- The cash ratio measures the company's ability to cover its current liabilities solely with cash and cash equivalents.
- Boston Scientific's cash ratio has varied over the years, reaching its peak at 0.73 in 2020. However, in 2023, the cash ratio has declined to 0.34.
- A higher cash ratio is generally preferred as it indicates a stronger ability to pay off short-term debts with cash on hand.
- The decrease in the cash ratio in 2023 may suggest that Boston Scientific has a lower proportion of cash and cash equivalents relative to its current liabilities.

In conclusion, while Boston Scientific Corp. maintains current ratios above 1, indicating a capability to cover short-term obligations, the declines in the quick ratio and cash ratio in 2023 may raise concerns about the company's liquidity position. Further analysis of the company's working capital management and cash flow trends may provide additional insights into its short-term liquidity health.

---

See also:

Boston Scientific Corp Liquidity Ratios

---

Additional liquidity measure

The cash conversion cycle of Boston Scientific Corp. has shown some fluctuation over the past five years. In 2023, the company's cash conversion cycle increased to 186.64 days from the previous year's 149.42 days, indicating a potential slowdown in the conversion of its inventory and receivables into cash. This could signify an increase in the time it takes for Boston Scientific to sell its products and collect payments from customers.

Comparatively, in 2021, the company managed to reduce its cash conversion cycle to 134.85 days, reflecting an improvement in its operational efficiency and ability to convert its working capital into cash more swiftly. However, in 2019, the cash conversion cycle was notably high at 183.63 days, suggesting potential inefficiencies in managing its working capital at that time.

Overall, the trend in Boston Scientific Corp.'s cash conversion cycle signals variations in its operational effectiveness and cash flow management over the years. It is essential for the company to closely monitor and optimize its cash conversion cycle to streamline its working capital management and enhance its overall financial performance.